semaglutide cardiovascular risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial Effects of semaglutide on risk

10.1172/JCI81975 J

The pure fraction containing the Semaglutide was pooled

Retatrutides unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes

Hard stool and straining and even diarrhea can lead to symptoms

Regularly eating fiber increases GLP-1 secretion due to the short-chain fatty acids produced in the microbiome

Clinical evidence consistently demonstrates that patients regain approximately one-third of lost weight within the first year of stopping GLP-1 therapy, with longer-term studies suggesting even more substantial rebound [50]